- Report
- February 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 129 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- February 2024
- 185 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Report
- February 2024
- 120 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- April 2023
- 120 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- November 2022
- 76 Pages
Global
From €1795EUR$2,000USD£1,545GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Report
- January 2025
- 132 Pages
Global
From €852EUR$950USD£734GBP
Dexlansoprazole is a proton pump inhibitor (PPI) used to treat gastroesophageal reflux disease (GERD) and other gastrointestinal disorders. It is a prescription medication that works by reducing the amount of acid produced in the stomach. It is available in both immediate-release and delayed-release formulations. Dexlansoprazole is also used to treat erosive esophagitis, a condition in which the lining of the esophagus is damaged by stomach acid. It is also used to treat ulcers, and to prevent ulcers from forming in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs).
Dexlansoprazole is a popular choice for treating GERD and other gastrointestinal disorders due to its effectiveness and relatively low side effects. It is generally well tolerated and has few drug interactions.
The Dexlansoprazole market is highly competitive, with many companies offering their own formulations of the drug. Some of the major players in the market include Takeda Pharmaceuticals, AstraZeneca, Pfizer, and Sun Pharmaceuticals. Show Less Read more